By admin 
Bristol-Myers Squibb Firm (NYSE:BMY) Goldman Sachs forty sixth Annual International Healthcare Convention June 11, 2025 10:00 AM ET
Firm Members
Adam Lenkowsky – Govt VP & Chief Commercialization Officer
Christopher S. Boerner – CEO & Chairman
Convention Name Members
Asad Haider – Goldman Sachs Group, Inc., Analysis Division
Asad Haider
All proper. However good about at time. So let’s get began. Welcome to day 3 of our Healthcare Convention. My title is Asad Haider, I am the U.S. pharmaceutical analyst at Goldman Sachs. I am very, very happy and privileged to have the Bristol-Myers staff over right here, Chris Boerner, Chairman and CEO; and Adam Lenkowsky, Chief Business Officer. Chris and Adam, welcome, and thanks for being with us.
Christopher S. Boerner
It is nice to be right here.
Adam Lenkowsky
Thanks.
Query-and-Reply Session
Asad Haider
So I assume simply let’s begin with a giant image query as a result of that is one thing that we’re actually asking our firms simply to form of examine the field and get it out of the best way, and that has to do with the exterior working setting, policy-related uncertainties which have been bearing down on the pharmaceutical sector. We have been listening to from firms all week on how a few of the conversations with the administration have a minimum of directionally been transferring in the best route, though caveated with the truth that it is nonetheless very early, and we do not know the place that is all going to land.
So possibly, Chris, simply speak to us about the way you’re fascinated about MFN within the context of your individual conversations with — and interactions with Washington, D.C., Type of what is the temper on the market? What are the vary of outcomes that you just suppose may occur?
Christopher S. Boerner
Properly, to begin with, it is nice to be right here. We’re clearly partaking with the administration. We have been partaking with